Institut Català de la Salut
[Aubets E, Ciudad CJ, Noé V] Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Nanoscience and Nanotechnology Institute, IN2UB, University of Barcelona, 08028 Barcelona, Spain. [Chillon M] ICREA, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-04-25T12:59:39Z
2022-04-25T12:59:39Z
2021-09
Adenovirus; Terapia contra el cáncer; Vectores virales
Adenovirus; Cancer therapy; Viral vectors
Adenovirus; Teràpia contra el càncer; Vectors virals
PolyPurine Reverse Hoogsteen Hairpins (PPRHs) are gene-silencing DNA-oligonucleotides developed in our laboratory that are formed by two antiparallel polypurine mirror repeat domains bound intramolecularly by Hoogsteen bonds. The aim of this work was to explore the feasibility of using viral vectors to deliver PPRHs as a gene therapy tool. After treatment with synthetic RNA, plasmid transfection, or viral infection targeting the survivin gene, viability was determined by the MTT assay, mRNA was determined by RT-qPCR, and protein levels were determined by Western blot. We showed that the RNA-PPRH induced a decrease in cell viability in a dose-dependent manner and an increase in apoptosis in PC-3 and HeLa cells. Both synthetic RNA-PPRH and RNA-PPRH intracellularly generated upon the transfection of a plasmid vector were able to reduce survivin mRNA and protein levels in PC-3 cells. An adenovirus type-5 vector encoding the PPRH against survivin was also able to decrease survivin mRNA and protein levels, leading to a reduction in HeLa cell viability. In this work, we demonstrated that PPRHs can also work as RNA species, either chemically synthesized, transcribed from a plasmid construct, or transcribed from viral vectors. Therefore, all these results are the proof of principle that viral vectors could be considered as a delivery system for PPRHs.
This research was funded by grant RTI2018-093901-B-I00 from Plan Nacional de Investigación Científica (Spain). Group holding the Quality Mention from Generalitat de Catalunya 2017-SGR-94. EA is awarded with fellowships from Generalitat de Catalunya (FI).
Article
Versió publicada
Anglès
Proteïnes - Inhibidors; Epigenètica; Oligonucleòtids; CHEMICALS AND DRUGS::Nucleic Acids, Nucleotides, and Nucleosides::Nucleotides::Polynucleotides::Oligonucleotides; PHENOMENA AND PROCESSES::Genetic Phenomena::Gene Expression Regulation::Epigenesis, Genetic::Gene Silencing; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Intracellular Signaling Peptides and Proteins::Apoptosis Regulatory Proteins::Inhibitor of Apoptosis Proteins::Survivin; COMPUESTOS QUÍMICOS Y DROGAS::nucleótidos y nucleósidos de ácidos nucleicos::nucleótidos::polinucleótidos::oligonucleótidos; FENÓMENOS Y PROCESOS::fenómenos genéticos::regulación de la expresión génica::epigénesis genética::silenciamiento génico; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intracelular::proteínas reguladoras de la apoptosis::proteínas inhibidoras de la apoptosis::survivina
MDPI
International Journal of Molecular Sciences;22(18)
https://doi.org/10.3390/ijms221810025
info:eu-repo/grantAgreement/ES/PE2017-2020/RTI2018-093901-B-I00
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]